JP2018521008A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521008A5 JP2018521008A5 JP2017560938A JP2017560938A JP2018521008A5 JP 2018521008 A5 JP2018521008 A5 JP 2018521008A5 JP 2017560938 A JP2017560938 A JP 2017560938A JP 2017560938 A JP2017560938 A JP 2017560938A JP 2018521008 A5 JP2018521008 A5 JP 2018521008A5
- Authority
- JP
- Japan
- Prior art keywords
- medi
- administration
- antibody
- binding fragment
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562167625P | 2015-05-28 | 2015-05-28 | |
| US62/167,625 | 2015-05-28 | ||
| PCT/EP2016/061987 WO2016189124A1 (en) | 2015-05-28 | 2016-05-27 | Therapeutic combinations and methods for treating neoplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018521008A JP2018521008A (ja) | 2018-08-02 |
| JP2018521008A5 true JP2018521008A5 (enExample) | 2019-06-27 |
Family
ID=56117679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560938A Ceased JP2018521008A (ja) | 2015-05-28 | 2016-05-27 | 腫瘍形成を処置するための治療用組成物および治療方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160347848A1 (enExample) |
| EP (1) | EP3303393A1 (enExample) |
| JP (1) | JP2018521008A (enExample) |
| KR (1) | KR20180011165A (enExample) |
| CN (1) | CN107743400A (enExample) |
| AR (1) | AR104812A1 (enExample) |
| AU (1) | AU2016269145C1 (enExample) |
| CA (1) | CA2986966A1 (enExample) |
| IL (1) | IL255780A (enExample) |
| RU (1) | RU2017144185A (enExample) |
| TW (1) | TW201705981A (enExample) |
| WO (1) | WO2016189124A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL321966A (en) | 2013-09-11 | 2025-09-01 | Medimmune Ltd | Anti-B7-H1 antibodies for tumor treatment |
| LT3142751T (lt) * | 2014-05-13 | 2019-09-25 | Medimmune Limited | Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui |
| WO2016030455A1 (en) * | 2014-08-28 | 2016-03-03 | Medimmune Limited | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| EP3292152A1 (en) | 2015-05-07 | 2018-03-14 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| JP2019514889A (ja) * | 2016-04-25 | 2019-06-06 | メディミューン，エルエルシー | 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物 |
| CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| IL307242B1 (en) | 2016-12-07 | 2026-07-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| UY37523A (es) * | 2016-12-15 | 2018-07-31 | Abbvie Biotherapeutics Inc | Anticuerpos anti-ox40 y sus usos |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| IL270743B2 (en) | 2017-05-19 | 2024-09-01 | Wuxi Biologics Shanghai Co Ltd | Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| KR102442736B1 (ko) | 2017-06-14 | 2022-09-16 | 에이디씨 테라퓨틱스 에스에이 | 항-cd19 adc의 투여를 위한 투약량 체제 |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| WO2020014583A1 (en) * | 2018-07-13 | 2020-01-16 | Bristol-Myers Squibb Company | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor |
| MX2021005048A (es) | 2018-10-31 | 2021-09-08 | Bioatla Inc | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. |
| BR112021012631A2 (pt) | 2018-12-26 | 2021-12-14 | Xilio Dev Inc | Anticorpos anti-ctla4 e métodos de uso dos mesmos |
| TWI907357B (zh) * | 2019-09-05 | 2025-12-11 | 瑞典商阿斯特捷利康公司 | 用於治療晚期肺癌之組成物及方法 |
| WO2021098851A1 (en) * | 2019-11-20 | 2021-05-27 | Eucure (Beijing) Biopharma Co., Ltd | Anti-ctla4/ox40 bispecific antibodies and uses thereof |
| GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
| US20230183366A1 (en) * | 2020-05-13 | 2023-06-15 | Inserm (Institut National De La Santé Et De La Recherch Médicale) | Recombinant proteins with ox40 activating properties |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| WO2025255012A1 (en) * | 2024-06-03 | 2025-12-11 | Uct Bioscience Co., Ltd. | Anti-grp78 antibody, immunoconjugate and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5821332A (en) | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
| US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7158164B2 (en) | 2003-08-29 | 2007-01-02 | Fuji Photo Film Co., Ltd. | Thermal development method and apparatus |
| EP1877090B1 (en) | 2005-05-06 | 2014-01-15 | Providence Health System | Trimeric ox40-immunoglobulin fusion protein and methods of use |
| WO2007056539A2 (en) | 2005-11-08 | 2007-05-18 | Medarex, Inc. | Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| US9828432B2 (en) | 2012-02-06 | 2017-11-28 | Providence Health & Services—Oregon | Cancer treatment and monitoring methods using OX40 agonists |
| HK1205691A1 (en) | 2012-03-02 | 2015-12-24 | Providence Health & Services - Oregon | Dual ox40 agonist/il-2 cancer therapy methods |
| MX2016007965A (es) * | 2013-12-17 | 2016-10-28 | Genentech Inc | Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1. |
| KR20160146747A (ko) * | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| CN107531773A (zh) * | 2015-03-11 | 2018-01-02 | 俄勒冈州普罗维登斯健康与服务部 | 用于增强癌症治疗的效果的组合物和方法 |
-
2016
- 2016-05-09 US US15/149,927 patent/US20160347848A1/en not_active Abandoned
- 2016-05-25 TW TW105116316A patent/TW201705981A/zh unknown
- 2016-05-27 AR ARP160101560A patent/AR104812A1/es unknown
- 2016-05-27 AU AU2016269145A patent/AU2016269145C1/en not_active Ceased
- 2016-05-27 JP JP2017560938A patent/JP2018521008A/ja not_active Ceased
- 2016-05-27 CN CN201680029691.5A patent/CN107743400A/zh active Pending
- 2016-05-27 KR KR1020177036356A patent/KR20180011165A/ko not_active Withdrawn
- 2016-05-27 WO PCT/EP2016/061987 patent/WO2016189124A1/en not_active Ceased
- 2016-05-27 RU RU2017144185A patent/RU2017144185A/ru not_active Application Discontinuation
- 2016-05-27 CA CA2986966A patent/CA2986966A1/en not_active Abandoned
- 2016-05-27 EP EP16728250.8A patent/EP3303393A1/en not_active Withdrawn
-
2017
- 2017-11-20 IL IL255780A patent/IL255780A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wen et al. | Chronic inflammation, cancer development and immunotherapy | |
| Rappaport et al. | A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results | |
| Makaremi et al. | Immune checkpoint inhibitors in colorectal cancer: challenges and future prospects | |
| Zhang et al. | The role of interleukin-17 in inflammation-related cancers | |
| Filimon et al. | Interleukin-8 in melanoma pathogenesis, prognosis and therapy—an integrated view into other neoplasms and chemokine networks | |
| JP2021058197A5 (enExample) | ||
| JP2018512397A5 (enExample) | ||
| Mahipal et al. | Immunotherapy in hepatocellular carcinoma: is there a light at the end of the tunnel? | |
| RU2017144185A (ru) | Терапевтические комбинации и способы лечения новообразований | |
| RU2017105425A (ru) | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины | |
| JP2019536430A5 (enExample) | ||
| Wang et al. | Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade | |
| Rafii et al. | Advancing CAR T-cell therapy in solid tumors: current landscape and future directions | |
| JP6917681B2 (ja) | 腫瘍性疾患のための治療 | |
| Janssen et al. | Combinatorial immunotherapies for metastatic colorectal cancer | |
| JP2011103891A5 (enExample) | ||
| Galindo-Pumarino et al. | Tumor microenvironment in metastatic colorectal cancer: the arbitrator in patients’ outcome | |
| CN103906536A (zh) | 恶病质治疗 | |
| Becht et al. | New opportunities in the systemic treatment of hepatocellular carcinoma—today and tomorrow | |
| Kim et al. | Strategies to overcome hurdles in cancer immunotherapy | |
| Chao et al. | Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma | |
| Tella et al. | Evaluating the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma: evidence to date | |
| Han et al. | Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo | |
| CN114042154B (zh) | 一种药物组合在制备抗肿瘤的联合治疗药物中的应用 | |
| Yang et al. | Liver metastasis of colorectal cancer: Mechanism and clinical therapy |